Patients Gain Access to Daraxonrasib After Trial Doubled Survival to 13.2 Months
Updated
Updated · The Boston Globe · Aug 17
Patients Gain Access to Daraxonrasib After Trial Doubled Survival to 13.2 Months
3 articles · Updated · The Boston Globe · Aug 17
Summary
Mass General Brigham and Dana-Farber patients with advanced pancreatic cancer are now receiving daraxonrasib outside clinical trials through a free expanded-access program while the drug awaits FDA approval.
In a 500-patient late-stage trial, the pill extended median survival to 13.2 months from 6.7 months and delayed tumor growth to 7.2 months from 3.6 months versus chemotherapy alone.
Daraxonrasib targets KRAS-driven tumors using a molecular-glue approach; KRAS mutations appear in more than 90% of pancreatic cancers, a disease with about 70,000 U.S. diagnoses a year.
Doctors and patients called the drug a breakthrough, but oncologists cautioned it is not a cure because cancers can develop resistance, pushing research toward combinations with chemotherapy, vaccines and mRNA therapies.
Why are some late-stage pancreatic cancer patients getting daraxonrasib now, and who may benefit most from this KRAS-targeting pill?
If daraxonrasib can extend survival after chemotherapy fails, what still stands between patients and wider access?
Daraxonrasib Doubles Survival in Metastatic Pancreatic Cancer: RASolute 302 Trial Results, FDA Fast-Track, and the New Era of RAS(ON) Inhibition
Overview
Daraxonrasib, a novel RAS(ON) inhibitor, has transformed the treatment landscape for metastatic pancreatic cancer by nearly doubling patient survival and significantly improving quality of life. Its unique mechanism—forming a tri-complex with cyclophilin A and active RAS—blocks critical cancer growth signals, leading to tumor shrinkage and less pain. The drug’s strong results in the RASolute 302 trial prompted the FDA to launch an Expanded Access Program and fast-track its review, aiming for rapid approval. With high tolerability, proactive side effect management, and ongoing trials exploring combinations to delay resistance, daraxonrasib offers new hope for patients facing aggressive, RAS-driven cancers.